Jaguar Health, Inc. is a biopharmaceutical company based in San Francisco focusing on plant-based medicines for gastrointestinal and other therapeutic areas.

# Summary of Jaguar Health, Inc.

## Company Overview
- **Industry:** Biopharmaceuticals / Natural Product Pharmaceuticals
- **Headquarters:** San Francisco, California
- **Stock Ticker:** JAGX (Nasdaq Capital Market)
- **Incorporation:** Delaware
- **I.R.S. Employer Identification No.:** 46-2956775

## Business Focus
Jaguar Health, Inc. specializes in developing and commercializing plant-based medicines primarily derived from natural sources. The company emphasizes ethnobotanical research, sustainable sourcing, and natural product chemistry to create pharmaceutical treatments with a focus on gastrointestinal health and other therapeutic areas.

## Company Operations and Management
- **Number of Employees:** (Not explicitly provided in the excerpt)
- **Major Executives and Directors:**
  - Lisa A. Conte: CEO and President
  - Pravin Chaturvedi, Ph.D.: Chief Scientific Officer
  - Steven R. King, Ph.D.: Chief of Sustainable Supply, Ethnobotanical Research, and IP Officer
  - Jonathan Wolin: Chief of Staff, General Counsel, and Chief Compliance Officer
- **Board of Directors:**
  - Includes individuals with venture capital and biotech industry expertise, such as James J. Bochnowski, John Micek III, Jonathan B. Siegel, and Anula Jayasuriya.

## Financial Highlights (as of Fiscal Year End December 31, 2024)
- **Total Revenue:** *Not explicitly provided or summarized in this excerpt.*
- **Net Income/Loss:** *Not explicitly provided or summarized in this excerpt.*
- **Market Capitalization (June 30, 2024):** Approximately **$28 million**, based on closing sales price on Nasdaq.

## Customer Base
- **Number of Customers:** *Not specified in the provided document.*

## Business Strategy and Focus
- The company emphasizes plant-based medicines targeting gastrointestinal conditions.
- It leverages ethnobotanical research and sustainable sourcing of botanicals like *Croton lechleri* (bloodroot or dragon’s blood tree) for the development of pharmaceuticals such as crofelemer.
- The company engages in strategic collaborations, licensing, and negotiations with venture and investment entities, including Streeterville Capital LLC and Iliad.

## Notable Product Development and Licensing
- The company focuses on developing medicines based on natural extracts, with a particular emphasis on gut health and related indications.
- It conducts ethnobotanical research to identify sustainable harvesting methods for natural compounds.
- The company has undertaken various private placements, warrant exchanges, and royalty interest transactions to fund ongoing operations and acquisitions.

## Additional Information
- The company does not disclose specific revenue, profit, or exact customer count in this excerpt.
- The company has a small, specialized leadership team and a board with diverse experience in biotech, venture capital, and healthcare.

---

**Note:** No explicit data on the number of customers, revenue, income, or employees is included in the provided excerpt; only organizational, strategic, and financial overview information is summarized.

Jaguar Health, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative plant-based therapies for gastrointestinal issues, primarily for patients with HIV/AIDS.

# Company Overview: Jaguar Health, Inc.

## General Information
Jaguar Health, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for patients with gastrointestinal (GI) issues. The company's primary product, **Mytesi** (crofelemer), is an FDA-approved prescription medicine used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

## Business Focus
- **Product Development**: Jaguar Health specializes in plant-based therapies and natural medicines derived from its proprietary botanical platform.
- **Target Indications**: The company is involved in developing treatments for various GI conditions, including:
  - Short bowel syndrome
  - HIV-related diarrhea
  - Chronic diarrheal disorders

## Operational Details
- **Customers**: 
  - Jaguar Health primarily serves healthcare providers, pharmacies, and patients suffering from GI disorders, particularly those related to HIV/AIDS.
- **Workforce**: The company maintains a dedicated team, comprising executive officers, scientific advisors, and other employees who are involved in research, development, marketing, and sales.

## Financial Performance
- **Revenue**: Specific revenue figures for the latest fiscal year are not provided in the content, but Jaguar Health's performance can be monitored through its product sales, primarily driven by the market acceptance of Mytesi.
- **Income**: The company has fluctuated in net loss as it invests heavily in research, development, and marketing to expand its offerings and market penetration.

## Company Structure
- **Employee Count**: While the exact number of employees isn't specified, the executive leadership team, including the CEO and other officers, plays a crucial role in operations and corporate governance.
  
## Market Position
Jaguar Health positions itself within the biopharmaceutical sector focused on specialty GI treatments, leveraging botanical medicines as an innovative approach to address unmet medical needs in patients with chronic GI conditions. The company's ability to secure FDA approvals and develop its product pipeline significantly impacts its growth trajectory and financial stability.

## Conclusion
Jaguar Health, Inc. is committed to advancing healthcare solutions for patients with compromised digestive health, with a clear focus on leveraging natural medicinal products. Its operational strategies and market initiatives aim to enhance both patient care and overall corporate growth in the competitive biopharmaceutical landscape.

Jaguar Health, Inc.

10-K / April 15, 2025

10-K / April 17, 2024

10-K / April 15, 2025

Summary of Jaguar Health, Inc.

Company Overview

Business Focus

Company Operations and Management

Financial Highlights (as of Fiscal Year End December 31, 2024)

Customer Base

Business Strategy and Focus

Notable Product Development and Licensing

Additional Information